215 related articles for article (PubMed ID: 33290900)
1. Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection.
Avdonkina NA; Danilova AB; Misyurin VA; Prosekina EA; Girdyuk DV; Emelyanova NV; Nekhaeva TL; Gafton GI; Baldueva IA
Pathol Res Pract; 2021 Jan; 217():153214. PubMed ID: 33290900
[TBL] [Abstract][Full Text] [Related]
2. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors.
Avdonkina NA; Danilova AB; Nekhaeva TL; Prosekina EA; Emelyanova NV; Novik AV; Girdyuk DV; Gafton GI; Baldueva IA
Immunobiology; 2021 Jul; 226(4):152094. PubMed ID: 34052775
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance.
Honoki K; Fujii H; Kubo A; Kido A; Mori T; Tanaka Y; Tsujiuchi T
Oncol Rep; 2010 Aug; 24(2):501-5. PubMed ID: 20596639
[TBL] [Abstract][Full Text] [Related]
6. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
9. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas.
Wunder JS; Czitrom AA; Kandel R; Andrulis IL
J Natl Cancer Inst; 1991 Feb; 83(3):194-200. PubMed ID: 1988704
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
Ha HT; Griffith KA; Zalupski MM; Schuetze SM; Thomas DG; Lucas DR; Baker LH; Chugh R
Am J Clin Oncol; 2013 Feb; 36(1):77-82. PubMed ID: 22237145
[TBL] [Abstract][Full Text] [Related]
11. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
14. ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children.
Aydin B; Akyuz C; Varan A; Yalcin B; Kurucu N; Kutluk T
Rev Recent Clin Trials; 2018; 13(2):126-131. PubMed ID: 29366426
[TBL] [Abstract][Full Text] [Related]
15. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B.
Mizushima E; Tsukahara T; Emori M; Murata K; Akamatsu A; Shibayama Y; Hamada S; Watanabe Y; Kaya M; Hirohashi Y; Kanaseki T; Nakatsugawa M; Kubo T; Yamashita T; Sato N; Torigoe T
Cancer Sci; 2020 Jan; 111(1):36-46. PubMed ID: 31705593
[TBL] [Abstract][Full Text] [Related]
17. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
[TBL] [Abstract][Full Text] [Related]
18. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
Reichardt P; Pink D; Tilgner J; Kretzschmar A; Thuss-Patience PC; Dörken B
Onkologie; 2002 Dec; 25(6):541-6. PubMed ID: 12566899
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M; Duan PG; Gao ZZ; Dai M
Oncol Rep; 2020 Dec; 44(6):2691-2700. PubMed ID: 33125503
[TBL] [Abstract][Full Text] [Related]
20. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin.
Wang SN; Luo S; Liu C; Piao Z; Gou W; Wang Y; Guan W; Li Q; Zou H; Yang ZZ; Wang D; Wang Y; Xu M; Jin H; Xu CX
Mol Ther; 2017 Sep; 25(9):2140-2149. PubMed ID: 28648665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
